Hengrui Pharma Sets Formal Remuneration and Evaluation Committee to Bolster Governance

The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).

Jiangsu Hengrui Pharmaceuticals has established a Remuneration and Evaluation Committee under its board to strengthen governance around pay and performance oversight for directors and senior management. The committee’s framework defines its composition, the predominance of independent directors, term rules, and support functions to ensure proper information flow and implementation of board decisions.

The committee is tasked with designing transparent remuneration policies, setting and reviewing pay structures, assessing executive performance, and recommending compensation packages aligned with market benchmarks and corporate goals. It will also approve service contract terms, termination and misconduct-related compensation, and remuneration for non-executive directors, aiming to ensure fairness, reasonableness, and compliance with Hong Kong listing and PRC corporate governance standards.

The most recent analyst rating on (HK:1276) stock is a Buy with a HK$92.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.

More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a China-based pharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines. It operates in the biopharmaceutical and healthcare sector and is listed in Hong Kong through its Class H shares, subject to the corporate governance and listing requirements of the Hong Kong Stock Exchange.

Average Trading Volume: 3,328,521

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$420.7B

For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.